Literature DB >> 27790456

Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study.

Bahram-Fariborz Farsad1, Mohammad Abbasinazari2, Atousa Dabagh3, Hooman Bakshandeh4.   

Abstract

INTRODUCTION: Anticoagulant control is assessed by Time in Therapeutic Range (TTR). For a given patient, TTR is defined as the duration of time in which the patient's International Normalized Ratio (INR) values were within a desired range. AIM: To assess TTR in patients receiving treatment with warfarin for non-valvular atrial fibrillation at a referral center for cardiovascular diseases in Tehran, Iran. MATERIALS AND
METHOD: Over 6 months, we enrolled eligible patients presenting to Shaheed Rajaie Hospital in Tehran for regular INR testing. Demographic data, medical history, and current medications were determined for all participants. TTR was assessed by the Rosendaal method.
RESULTS: A total of 470 patients (mean age 58.0±14.2 years, 60.2% women) underwent 1450 INR measurements. The mean TTR was calculated as 54.9±11.9%. Of the sample patients, 37.3% were in the good control category (TTR > 70%), 24.6% were in the intermediate category (50% < TTR < 70%), and 38.1% were in the poor control category (TTR < 50%). The number of current medications above four was a significant predictor of poor control (OR = 2.06; 95% CI, 1.87, 2.23). The mean TTR of the studied patients (54.9%) was below the good control range.
CONCLUSION: The quality of anticoagulant therapy with warfarin in Iranian patients was poorer than that reported in European countries. Based on these results, research considering the causes of poor TTR among Iranian patients is recommended.

Entities:  

Keywords:  Anticoagulant; International Normalized Ratio; Iranian patients

Year:  2016        PMID: 27790456      PMCID: PMC5071956          DOI: 10.7860/JCDR/2016/21955.8457

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  20 in total

1.  Vitamin K antagonist treatment in patients with atrial fibrillation and time in therapeutic range in four European countries.

Authors:  François-Emery Cotté; Hicham Benhaddi; Isabelle Duprat-Lomon; Adam Doble; Nick Marchant; Alexia Letierce; Michael Huguet
Journal:  Clin Ther       Date:  2014-08-21       Impact factor: 3.393

2.  Warfarin: almost 60 years old and still causing problems.

Authors:  Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

3.  Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range.

Authors:  Pilar Gallego; Juan Antonio Vilchez; Deirdre A Lane
Journal:  Circulation       Date:  2013-05-02       Impact factor: 29.690

Review 4.  Drug and dietary interactions of warfarin and novel oral anticoagulants: an update.

Authors:  Edith Nutescu; Ittiporn Chuatrisorn; Erika Hellenbart
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

5.  Quality of anticoagulation control among patients with atrial fibrillation.

Authors:  Osnat C Melamed; Gilad Horowitz; Asher Elhayany; Shlomo Vinker
Journal:  Am J Manag Care       Date:  2011-03       Impact factor: 2.229

6.  Patient-reported medication adherence barriers among patients with cardiovascular risk factors.

Authors:  Leah L Zullig; Karen M Stechuchak; Karen M Goldstein; Maren K Olsen; Felicia M McCant; Susanne Danus; Matthew J Crowley; Eugene Z Oddone; Hayden B Bosworth
Journal:  J Manag Care Spec Pharm       Date:  2015-06

7.  Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.

Authors:  Elaine M Hylek; Alan S Go; Yuchiao Chang; Nancy G Jensvold; Lori E Henault; Joe V Selby; Daniel E Singer
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

8.  A method to determine the optimal intensity of oral anticoagulant therapy.

Authors:  F R Rosendaal; S C Cannegieter; F J van der Meer; E Briët
Journal:  Thromb Haemost       Date:  1993-03-01       Impact factor: 5.249

Review 9.  A Summary of the Literature Evaluating Adherence and Persistence with Oral Anticoagulants in Atrial Fibrillation.

Authors:  Kehinde O Obamiro; Leanne Chalmers; Luke R E Bereznicki
Journal:  Am J Cardiovasc Drugs       Date:  2016-10       Impact factor: 3.571

Review 10.  Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review.

Authors:  Yi Wan; Carl Heneghan; Rafael Perera; Nia Roberts; Jennifer Hollowell; Paul Glasziou; Clare Bankhead; Yongyong Xu
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-11-05
View more
  8 in total

1.  Assessment of the quality of anticoagulation management with warfarin in a tertiary care center.

Authors:  Monirah A Albabtain; Maha M Alharthi; Khalid Dagriri; Amr A Arafat; Esraa Ayrout; Yahya Alhebaishi; Ahmed AlFagih
Journal:  Saudi Med J       Date:  2020-11       Impact factor: 1.484

2.  Evaluation of Warfarin Anticoagulation at University of Gondar Comprehensive Specialized Hospital, North-West Ethiopia.

Authors:  Nahusenay Masresha; Esileman Abdela Muche; Asmamaw Atnafu; Ousman Abdela
Journal:  J Blood Med       Date:  2021-03-23

3.  Extending INR testing intervals in warfarin patients at a multi-center anticoagulation clinic.

Authors:  Michelle Papala; Deborah Gillard; Jennifer Hardman; Teresa Romano; Lisa E Rein
Journal:  J Thromb Thrombolysis       Date:  2021-10-08       Impact factor: 5.221

4.  Development of an interview-based warfarin nomogram predicting the time spent in the therapeutic INR range: A cost-effective, and non-invasive strategy building from a cross sectional study in a low resource setting.

Authors:  Aishwarya Anand; Rupesh Kumar; Ankur Gupta; Rajesh Vijayvergiya; Saurabh Mehrotra; Deepesh Lad; Parag Barwad; Swati Sharma; Amol N Patil
Journal:  Indian Heart J       Date:  2022-03-25

Review 5.  Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review.

Authors:  Tamrat Assefa Tadesse; Gobezie Temesgen Tegegne; Dejuma Yadeta; Legese Chelkaba; Teferi Gedif Fenta
Journal:  Thromb J       Date:  2022-10-03

6.  Rosendaal linear interpolation method appraising of time in therapeutic range in patients with 12-week follow-up interval after mechanical heart valve replacement.

Authors:  Xiliang Zhu; Xijun Xiao; Sheng Wang; Xianjie Chen; Guoqing Lu; Xiaoyang Li
Journal:  Front Cardiovasc Med       Date:  2022-09-09

7.  Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms.

Authors:  Katharina Luise Schneider; Melanie Kunst; Ann-Kristin Leuchs; Miriam Böhme; Klaus Weckbecker; Kathrin Kastenmüller; Markus Bleckwenn; Stefan Holdenrieder; Christoph Coch; Gunther Hartmann; Julia Carolin Stingl
Journal:  Front Pharmacol       Date:  2020-01-28       Impact factor: 5.810

8.  Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia.

Authors:  Nuredin Shiferaw Yimer; Alfoalem Araba Abiye; Shemsu Umer Hussen; Tamrat Assefa Tadesse
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.